EMN-COVID: COVID-19 Infection and Multiple Myeloma
Study Details
Study Description
Brief Summary
Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Coronavirus Disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), is a highly contagious disease that appeared in Wuhan, Hubei province of China in December 2019. It has now spread to multiple countries through infected persons travelling mainly by air. Most of the infected patients have mild symptoms including fever, fatigue and cough. But in severe cases, patients can progress rapidly and develop the acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulopathy including a disseminated intravascular coagulation (DIC).
Multiple myeloma (MM) is a mature B-cell malignancy largely affecting the older patient with a median age at presentation of 70 years. The general performance status (PS) and the presence of comorbidity can identify a group of patients with poor tolerance to treatment, as well as risks of both bacterial and viral infection. MM patients have benefited significantly from therapeutic developments, however, the host response biology of the older person, coupled with a distinct disease biology overlay induces immune dysfunction. For example, the impact of aging on the human immune system is well documented. In MM it has long-since been understood that there is a spectrum of immune dysregulation, an important host factor considered in the "Hallmarks of cancer" theory. In addition, the delivery of anti-MM therapy includes immune modulating agents such as steroids, proteasome inhibitors and CD38-directed therapy though not all immune modulation is necessarily detrimental.
As such, myeloma patients are considered a higher risk in the current pandemic with SARS-COVID19. However, it is not clear whether this is actually the case, and the risk may not be different to population in general. Equally it may be sub-groups of patients who are at risk e.g. on treatment versus stable response (plateau), frailty. AS such, this proposal aims to collect in an observational study, the outcomes of COVID19 infection in MM patients across Europe.
Study Design
Outcome Measures
Primary Outcome Measures
- Nature of COVID19 [1 years]
The duration of infection.
- Costs related to COVID-19 [1 years]
Costs related to Covid in terms of health resource needs.
- Systemic anti-cancer therapy subgroup [1 years]
Number of infection recovery for each systemic anti-cancer subgroup.
- Laboratory values collected at hospitalization [1 years]
Evaluate if recurring haematological and chemistry values are related to infection onset, better or poorer outcome.
- COVID-19 infection in myeloma patient subgroups [1 years]
Number of infection in each myeloma patient subgroups and evaluation of the number of recovery per subgroup.
- Incidence of COVID-19 infection in frail patients [1 years]
Number of frail patients with COVID-19 infection and resolution of it.
- Infection outcome in different countries [1 years]
Number of infection and outcome per country.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Multiple Myeloma patients
-
COVID-19 infection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | General Hopspital Vienna/Medical University | Vienna | Austria | ||
| 2 | UCL Saint-Luc | Brussels | Belgium | ||
| 3 | University Hospital Ostrava | Ostrava | Czechia | ||
| 4 | University Hospital Würzburg | Würzburg | Germany | ||
| 5 | Alexandra Clinical Terapeutics | Athens | Greece | ||
| 6 | AOU Consorziale Policlinico di Bari | Bari | Italy | ||
| 7 | Amsterdam UMC | Amsterdam | Netherlands | ||
| 8 | St James's University Hospital | Leeds | United Kingdom |
Sponsors and Collaborators
- European Myeloma Network
- Fondazione EMN Italy Onlus
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EMN-COVID